A recent study published in the journal Dermatology found that in patients with both hidradenitis suppurativa (HS) and psoriasis, the disease diagnosed first tended to take a more severe course than the later diagnosed.
Researchers sought to characterize patients with both HS and psoriasis in terms of disease onset, course, severity, and management as well as comorbidities and disease. Their retrospective study included 28 patients with confirmed diagnosis of both diseases from two university hospitals between 2015 and 2019. Patients were divided into different cohorts based on whether HS or psoriasis was diagnosed first.
Among the 28 included patients (average age, 44 years), 15 patients were diagnosed first with HS at an average age of 22.8 years and 13 patients were diagnosed with psoriasis at 21.7 years. The onset of the second disease occurred at an average time of 14.3 years.
For patients with HS diagnosed first, the disease was significantly more severe compared with patients with psoriasis first; the mean highest International Hidradenitis Suppurativa Severity Score System scores were 23.5 and 8.2, respectively (P=.02). Conversely, psoriasis in patients with the disease diagnosed first had a more severe case than patients with HS first, though the difference was not considered significant (mean highest Psoriasis Area and Severity Index, 13.2 vs 7.8, respectively; P=.299).
The most common comorbidities among patients with HS and psoriasis were obesity (63%(, psychiatric complaints (25%), and psoriatic arthritis (21.4%). Adalimumab was the most commonly used therapy.
“In patients with a coprevelence of HS and [psoriasis], the disease which occurs first appears to take a severer course,” the authors wrote.
Reference
Pinter A, Sarlak M, Zeiner KN, et al. Coprevalence of hidradenitis suppurativa and psoriasis: detailed demographic, disease severity and comorbidity pattern. Dermatology. Published online December 16, 2020. doi:10.1159/000511868
